Citius Oncology (CTOR) Gains from Investment Securities (2023 - 2026)

Citius Oncology's Gains from Investment Securities history runs 4 years deep, the most recent figure standing at $18.1 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 214.78% year-over-year to $18.1 million; the TTM figure through Mar 2026 stood at $18.1 million (up 214.78% YoY), while the FY2025 annual figure was $18.1 million, up 41.96% from the prior year.
• Gains from Investment Securities was $18.1 million for Q1 2026 at Citius Oncology, roughly flat from $18.1 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $18.1 million in Q3 2025 to a low of $200000.0 in Q1 2024.
• Historically, Gains from Investment Securities has averaged $8.0 million across 4 years, with a median of $5.8 million in 2024.
• Biggest YoY gain for Gains from Investment Securities was 2775.0% in 2025; the steepest drop was 41.96% in 2025.
• A 4-year view of Gains from Investment Securities shows it stood at $660000.0 in 2023, then jumped by 771.21% to $5.8 million in 2024, then jumped by 214.78% to $18.1 million in 2025, then changed by 0.0% to $18.1 million in 2026.
• The last three Gains from Investment Securities figures came in at $18.1 million (Q1 2026), $18.1 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.